Introduction
============

Hypertension is a major independent risk factor for coronary artery disease, stroke, and renal failure. Reducing blood pressure (BP) below the target goal is important to prevent cardiovascular and cerebrovascular events.[@b1-dddt-9-2847] Various kinds of antihypertensive drugs such as diuretics, calcium channel blockers, beta blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin-receptor blockers (ARBs) have been used to lower BP effectively. Fimasartan is a new antihypertensive drug that lowers BP by blocking the angiotensin II type 1 receptor.[@b2-dddt-9-2847] The efficacy of fimasartan in reducing office-measured BP was shown to be greater than that of losartan.[@b3-dddt-9-2847] Maintenance of 24-hour BP reduction by fimasartan was comparable to or slightly better than by valsartan.[@b4-dddt-9-2847] The safety profile of fimasartan was also similar to losartan and valsartan.[@b3-dddt-9-2847],[@b4-dddt-9-2847]

Despite the availability of various antihypertensive drugs, achieving target BP is difficult in the majority of patients with hypertension, although the control rate is improving.[@b5-dddt-9-2847],[@b6-dddt-9-2847] Most patients require a combination of two or more drugs to achieve their target BP because effective BP reduction is difficult with monotherapy.[@b7-dddt-9-2847] The drug commonly used in combination with ARBs is hydrochlorothiazide (HCTZ). Several studies have demonstrated enhanced BP reduction with combinations of a renin--angiotensin--aldosterone system (RAAS) inhibitor and HCTZ compared to either treatment alone.[@b8-dddt-9-2847]--[@b10-dddt-9-2847] Because administration of HCTZ alone reduces plasma volume and activates the RAAS,[@b11-dddt-9-2847] the addition of a RAAS inhibitor to HCTZ may offset the diuretic-induced increase in plasma renin activity and could theoretically attenuate the metabolic effects of HCTZ.

The primary purpose of the study reported here was to compare the BP-lowering efficacy of fimasartan alone with that of fimasartan/HCTZ combination treatment in patients whose BP goal was not achieved after 4 weeks of treatment with once-daily fimasartan 60 mg.

Methods
=======

Patients
--------

Male and female patients aged 18 years and above were enrolled in the study if they met the following criteria: on the screening visit, mean values of two sitting diastolic blood pressure (siDBP) readings had to be \<110 mmHg if the patient were on antihypertensive medication; if the patient were antihypertensive naïve, the mean values of two siDBP readings had to be ≥90 mmHg and \<120 mmHg. Patients were excluded if they had: a mean sitting systolic blood pressure (siSBP) ≥200 mmHg at the screening visit; a difference of siSBP ≥20 mmHg or siDBP ≥10 mmHg between arms; secondary hypertension (ie, renovascular hypertension, endocrinologic disease, and use of hormonal contraceptives or drugs affecting BP); hepatic (aspartate transaminase and alanine transaminase ≥2.0× upper limit of normal) or renal impairment (serum creatinine ≥1.5× upper limit of normal); active hepatitis B or C (including carriers); positive status for HIV; known allergy to the study drugs; a sodium (\<133 mmol/L or ≥145 mmol/L) or potassium (\<3.5 mmol/L or ≥5.5 mmol/L) electrolyte imbalance; insulin-dependent or uncontrolled diabetes mellitus (glycated hemoglobin \[HbA~1C~\] \>9%); retinal hemorrhage or exudates within the previous 6 months; drug or alcohol dependency; heart or cerebrovascular disease within the previous 6 months (coronary heart disease, heart failure, significant valvular heart disease, cerebral infarction, or cerebral hemorrhage); active inflammatory gastrointestinal disease in the preceding 12 months or a history of gastrointestinal surgery or disease that could interfere with drug absorption; or the presence of a wasting disorder, autoimmune disease, or connective tissue disease. Women who were pregnant, breastfeeding, or those with child-bearing potential who were not sterilized and had no intention of using a contraceptive were also excluded.

Study design
------------

The study was conducted at 18 institutions in Korea as a multicenter, randomized, active-controlled, double-blind, parallel-group, dose-titration trial. The study design was approved by the Korea Food and Drug Administration and the institutional review board of each site. After screening, patients who met the eligibility criteria were given once-daily fimasartan 60 mg for 4 weeks. Patients already receiving antihypertensive therapy discontinued taking their previously prescribed drugs and were directly rolled into once-daily fimasartan 60 mg without a washout period. After 4 weeks of treatment with once-daily fimasartan 60 mg, patients with siDBP ≥90 mmHg were randomly assigned to receive either once-daily fimasartan 60 mg/HCTZ 12.5 mg or fimasartan 60 mg for 4 weeks at a 2:1 ratio by using sealed envelopes with the randomization number. The dose of the study drug was increased to fimasartan 120 mg/HCTZ 12.5 mg or fimasartan 120 mg then maintained for another 4 weeks if the siDBP was still \>90 mmHg after 4 weeks of treatment with fimasartan 60 mg/HCTZ 12.5 mg and fimasartan 60 mg. The study-drug dose was maintained in patients whose siDBP was \<90 mmHg.

All patients were instructed to take the study drug once daily between 6 am and 10 am for the study duration. Patients were instructed to fast for 12 hours prior to the scheduled visit and to refrain from taking the study medication in the morning before trough BP measurement. At each visit, after at least 5 minutes of rest in a sitting position, siSBP, siDBP, and pulse rate were measured twice with a 1-minute interval between measurements in the same arm using a semiautomated sphygmomanometer (HEM-7080IT \[equivalent to 705IT\], Omron Corporation, Kyoto, Japan).[@b12-dddt-9-2847] The average of the two sitting BP measurements was used. All adverse events were evaluated and recorded at each visit.

Efficacy evaluation
-------------------

This study was designed to compare the antihypertensive efficacy of fimasartan 60 mg/HCTZ 12.5 mg combination treatment to that of treatment with fimasartan 60 mg alone in patients who did not achieve the target BP after 4 weeks of treatment with fimasartan 60 mg.

The primary goal of this study was to compare the changes in mean siDBP from the baseline to Week 4 of treatment with the study drug (fimasartan 60 mg/HCTZ 12.5 mg) and the control drug (fimasartan 60 mg) in patients who did not achieve target siDBP after 4 weeks of prior treatment with once-daily fimasartan 60 mg.

The secondary efficacy points were: (1) change of mean siSBP from baseline at 4 and 8 weeks; (2) BP control rate (a proportion of patients who achieved mean siDBP \<90 mmHg) and response rate (a proportion of patients who achieved a reduction of siDBP ≥10 mmHg from baseline and/or a mean siDBP \<90 mmHg) at 4 and 8 weeks; and (3) change of mean siDBP from baseline at 8 weeks.

Safety evaluation
-----------------

Safety and tolerability were assessed at each visit by physical examination, direct questioning, and clinical laboratory test. Blood and urine samples were collected for laboratory tests at baseline, Week 4, and Week 8. Electrocardiography was performed at screening and at the end of the study. All adverse events that occurred during the study and details of their nature, occurrence, and elimination date, duration, severity, significance, and the relationship with the study drug were recorded.

Sample size
-----------

To identify the primary hypothesis, we assumed a potential difference of 3 mmHg in mean change of siDBP with a standard deviation of 7.5 mmHg between the two therapies.[@b3-dddt-9-2847],[@b13-dddt-9-2847]--[@b19-dddt-9-2847] With a randomization ratio of 2:1 between patients assigned fimasartan 60 mg/HCTZ 12.5 mg and those assigned fimasartan 60 mg, significance level of 5%, and statistical power of 80%, the total number of required subjects was 225 (150 for fimasartan 60 mg/HCTZ 12.5 mg and 75 for fimasartan 60 mg). Allowing for a drop-out rate of 10%, the total number of subjects to be enrolled was estimated to be 250 (167 for the study drug and 83 for the control drug). The number of subjects required for screening, assuming a nonresponder rate of 50%, was estimated to be approximately 500.

Statistical analyses
--------------------

For efficacy analysis, the intention-to-treat (ITT) analysis set was used for the main analysis while the per-protocol (PP) analysis set was additional. The ITT analysis set included all subjects with efficacy assessment variables for at least one time after randomization. Among the ITT population, the PP analysis set included subjects who completed the study without major or serious protocol violations. If any efficacy assessment variables were missed, they were imputed by the last-observation-carried-forward method. For safety analysis, we included all subjects who received the investigational drug at least once. Subjects who had been enrolled in the study but dropped out before drug administration were excluded. Safety assessment variables were not imputed for missed data.

The changes from baseline in siDBP and siSBP of the two groups at the end of 4 and 8 weeks of treatment were compared by two-sample *t*-test. In addition, we conducted analysis of covariance for changes of siDBP with baseline siDBP and investigation centers as covariates, and the two treatment groups as the factor. Descriptive statistics for the rates of the responders (siDBP \<90 mmHg or siDBP reduction from the baseline ≥10 mmHg) and control subjects (siDBP \<90 mmHg) at Weeks 4 and 8 were calculated and the differences between the two groups were analyzed by Pearson's chi-square.

Adverse events were coded using the *Medical Dictionary for Regulatory Activities* (MedDRA; v 13.0) and the percentage of the subjects who experienced any adverse events was determined. The chi-square test was also performed to analyze group differences. The incidence rates are presented by severity and causal relationship with each drug.

Demographic characteristics were compared between the two groups using the *t*-test or Wilcoxon rank-sum test for continuous variables and the chi-square test or Fisher's exact test for categorical variables. All data were analyzed using SAS^®^ software (v 9.2; SAS Institute, Cary, NC, USA) and all tests were done at a significance level of 5% using a two-sided test.

Results
=======

Patients' disposition
---------------------

Among 654 patients screened, 263 were matched to eligible randomization criteria after 4 weeks of treatment with once-daily fimasartan 60 mg. Of the 263 patients, 175 were assigned to 4 weeks of fimasartan/HTCZ treatment and 88 were assigned to 4 weeks of fimasartan treatment ([Figure 1](#f1-dddt-9-2847){ref-type="fig"}). Among the remaining 391 patients who were not randomized, 233 (59.6%) had a diastolic BP \<90 mmHg meeting the exclusion criterion of randomization. Thirty patients discontinued the study after randomization. Of these, six discontinued because of inclusion/exclusion deviation, 14 for consent withdrawal, five for adverse events, two for unsatisfactory responses, and three for other reasons.

Of the 263 patients, 256 were included in the primary efficacy analysis and seven were excluded because of missing efficacy data. There were no significant differences in baseline characteristics between the groups with the exception of the number of smokers ([Table 1](#t1-dddt-9-2847){ref-type="table"}). The number of smokers was higher in the fimasartan/HCTZ group than in the fimasartan group. The mean age was 54.7±9.1 years. The majority of patients were men (76.6%). Among the prior medication taken by the patients, one had been on a cardiac drug (nicorandil), and another took a peripheral vasodilator (nicametate citrate). The baseline siDBP and siSBP were not different between the treatment groups (*P*=0.7032 and 0.4015, respectively).

Efficacy
--------

The means of trough siDBP and siSBP at baseline, Week 4, and Week 8 are presented in [Table 2](#t2-dddt-9-2847){ref-type="table"}. The reduction of siDBP and siSBP was greater in the fimasartan/HCTZ group than in the fimasartan group. The reduction of siDBP was 6.88±8.10 mmHg in the fimasartan/HCTZ group and 3.38±7.33 mmHg in the fimasartan group at Week 4 (*P*=0.0008). The difference in siDBP reduction between the treatment groups was −3.35 mmHg (95% confidence interval: −5.39 to −1.32, *P*=0.0013 by analysis of covariance). At Week 8, the reduction in siDBP was 8.67±9.39 mmHg in the fimasartan/HCTZ group and 5.02±8.27 mmHg in the fimasartan group (*P*=0.0023). The reduction in siSBP was 10.50±13.76 mmHg in the fimasartan/HCTZ group and 5.75±12.18 mmHg in the fimasartan group at Week 4 (*P*=0.0069). At Week 8, the reduction in siSBP was 13.45±15.15 mmHg in the fimasartan/HCTZ group and 6.84±13.57 mmHg in the fimasartan group (*P*=0.0007).

When the fimasartan dose of both treatment groups was increased to 120 mg in patients who did not achieve the target siDBP (≥90 mmHg) at Week 4, siDBP and siSBP decreased significantly by Week 8 ([Table 3](#t3-dddt-9-2847){ref-type="table"}). Although there was no statistical significance, the fimasartan/HCTZ group showed greater reduction of siDBP and siSBP compared to the fimasartan group. Reduction in siDBP was 5.72±9.34 mmHg in the fimasartan/HCTZ group and 3.64±6.97 mmHg in the fimasartan group (*P*=0.1922). Reduction in siSBP was 7.86±15.40 mmHg in the fimasartan/HCTZ group and 4.45±11.45 mmHg in the fimasartan group (*P*=0.1943).

The responses and control rates are displayed in [Figure 2](#f2-dddt-9-2847){ref-type="fig"}. The response rate at Week 4 was 53.6% (90/168) in the fimasartan/HCTZ group and 39.8% (35/88) in the fimasartan group (*P*=0.0359). At Week 8, the response rate was 63.1% (106/168) in the fimasartan/HCTZ group and 51.1% (45/88) in the fimasartan group, which was not statistically different (*P*=0.0647). In the PP analysis, the response rate of the fimasartan/HTCZ treatment group was higher than that of the fimasartan treatment group (at Week 4, 55.7% vs 40.2%, *P*=0.0245 and, at Week 8, 67.1% vs 52.4%, *P*=0.0280). Although there was no statistically significant difference, the fimasartan/HCTZ group had a higher control rate at Weeks 4 and 8.

Safety and tolerability
-----------------------

In the safety-analysis population, the incidence of adverse events considered to be at least partly related to the study drugs was 11.79% ([Table 4](#t4-dddt-9-2847){ref-type="table"}). The incidence of adverse events did not differ between the treatment groups. The most common adverse events were headache and dizziness. There was no statistically significant difference in the incidence of headache and dizziness between the treatment groups (*P*=0.0698 and 0.6568, respectively). Among the other adverse events with an incidence of \<1%, patients in the fimasartan group reported constipation, nausea, and palpitation. Patients in the fimasartan/HCTZ group reported chest discomfort, asthenia, pruritus, erectile dysfunction, and flushing sensations. There were no serious adverse events related to the study-drug treatment.

The incidence of significant changes in laboratory parameters was small. In both treatment groups, the elevation of aspartate transaminase or alanine transaminase in three patients was noted to be treatment related. The level of serum potassium increased to 5.3 mmol/L at Week 8 from 4.7 mmol/L at baseline and 4.3 mmol/L at Week 4 in a patient from the fimasartan/HCTZ treatment group. The level of serum sodium decreased to 124 mmol/L at Week 8, from 135 mmol/L at baseline, and 127 mmol/L at Week 4 in a patient from the fimasartan/HCTZ treatment group.

Discussion
==========

As far as we are aware, this is the first study to have demonstrated that combination treatment with fimasartan and HCTZ is effective in the treatment of patients with essential hypertension who respond poorly to fimasartan monotherapy. Similar to the studies that evaluated combination ARB and HCTZ treatment,[@b8-dddt-9-2847],[@b10-dddt-9-2847],[@b20-dddt-9-2847],[@b21-dddt-9-2847] the combination treatment of fimasartan and HCTZ had better efficacy than fimasartan monotherapy. After 4 weeks of treatment, the combination of fimasartan and HCTZ was more effective in reducing siDBP and siSBP than fimasartan monotherapy. The difference in reduction of siDBP and siSBP between combination treatment and monotherapy was statistically significant (*P*\<0.05). The enhanced BP-lowering effect of combination therapy persisted over 8 weeks of treatment with optional dose escalation. The combination treatment showed a significantly higher responder rate at Weeks 4 and 8. Although not significant, the control rate of the combination treatment was higher than that of the monotherapy. The magnitude of BP lowering was comparable to other combination treatments of ARBs and HCTZ although they cannot be compared directly due to differences in study design.[@b9-dddt-9-2847],[@b10-dddt-9-2847],[@b22-dddt-9-2847] The difference in BP lowering between 8 weeks treatment of valsartan 160 mg plus HTCZ 12.5 mg and valsartan 160 mg was approximately 2.0 mmHg in siDBP and 3.7 mmHg in siSBP.[@b22-dddt-9-2847] Combination olmasartan and HCTZ treatment also showed similar BP lowering compared to monotherapy (siDBP: \~3.4 mmHg, siSBP: \~5.3 mmHg).[@b10-dddt-9-2847]

In the current study, the difference in BP lowering after 4 weeks' treatment was 3.50 mmHg in siDBP and 4.75 mmHg in siSBP. Fimasartan in combination with HCTZ was safe and well tolerated. The incidence of adverse events related to the study-drug treatment was small. There were no serious adverse events related to the study-drug treatment. The most frequent adverse events were headache and dizziness. The incidence did not differ between the treatment groups, and was also comparable to that reported in the previous Phase II and III studies of fimasartan.[@b3-dddt-9-2847],[@b23-dddt-9-2847] In terms of biochemical abnormalities, hypokalemia is a commonly associated biochemical abnormality of HCTZ.[@b24-dddt-9-2847],[@b25-dddt-9-2847] In the current study, no patient exhibited hypokalemia. It may be the addition of ARB which resulted in favorable effects regarding the biochemical abnormalities associated with HCTZ. Another biochemical abnormality associated with HCTZ is increase in triglyceride,[@b26-dddt-9-2847] which appeared in only one patient in the current study. Three patients experienced treatment-related elevation of liver enzyme after escalation of the fimasartan dose to 120 mg/day. The elevated liver enzyme level in two patients returned to normal at the follow-up examination without intervention. The persistent elevation of liver enzyme in the remaining patient at the follow-up examination was concluded to be related to drinking alcohol. The elevation of liver enzyme at the higher dose is consistent with previous studies[@b3-dddt-9-2847],[@b4-dddt-9-2847],[@b23-dddt-9-2847] and improved without intervention.

Limitations
===========

A limitation of the current study is that a dose-dependent reduction in BP was not presented, because the study design did not aim at evaluating the dose--response relation. Despite this limitation, dose escalation of fimasartan/HCTZ to 120 mg/12.5 mg or fimasartan 120 mg in patients who did not achieve the target siDBP at Week 4 resulted in significant reductions in siDBP and siSBP at Week 8, indicating a dose-dependent BP-lowering effect.

Another limitation is that the effect of combination treatment with HCTZ 25 mg was not evaluated. Although several studies have shown that 25 mg of HCTZ is more effective in lowering BP, we did not evaluate HCTZ at that dose because of potential biochemical abnormalities such as potassium depletion or uric acid elevation.[@b8-dddt-9-2847],[@b9-dddt-9-2847]

Conclusion
==========

The results of the current study suggest that combination treatment with fimasartan and HCTZ is effective in patients with hypertension which is not adequately controlled with fimasartan alone. The safety and tolerability of combination fimasartan and HCTZ treatment are comparable to those of fimasartan monotherapy.
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![Subject disposition and reasons for drop out.\
**Abbreviation:** HCTZ, hydrochlorothiazide.](dddt-9-2847Fig1){#f1-dddt-9-2847}

![(**A**) Response and (**B**) control rate of fimasartan/hydrochlorothiazide (HCTZ) and fimasartan at Weeks 4 and 8 from baseline.](dddt-9-2847Fig2){#f2-dddt-9-2847}

###### 

Baseline characteristics of study population

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                              Fimasartan/HCTZ\   Fimasartan\     Total\         *P*-value[\*](#tfn1-dddt-9-2847){ref-type="table-fn"}
                                              (N=168)            (N=88)          (N=256)        
  ------------------------------------------- ------------------ --------------- -------------- -------------------------------------------------------
  Age (years), mean (SD)                      55.3 (9.40)        53.4 (8.20)     54.7 (9.10)    0.1057[a](#tfn2-dddt-9-2847){ref-type="table-fn"}

  Weight (kg), mean (SD)                      71.9 (9.70)        71.3 (9.10)     71.7 (9.50)    0.6515[a](#tfn2-dddt-9-2847){ref-type="table-fn"}

  Height (cm), mean (SD)                      166.8 (6.80)       166.6 (7.90)    166.7 (7.20)   0.8069[a](#tfn2-dddt-9-2847){ref-type="table-fn"}

  Sex, n (%)                                                                                    0.4607[c](#tfn4-dddt-9-2847){ref-type="table-fn"}

   Male                                       131 (77.98)        65 (73.86)      196 (76.56)    

   Female                                     37 (22.02)         23 (26.14)      60 (23.44)     

  Smoking, n (%)                                                                                0.0095[c](#tfn4-dddt-9-2847){ref-type="table-fn"}

   Non-smoker                                 77 (45.83)         48 (54.55)      125 (48.83)    

   Past smoker                                44 (26.19)         30 (34.09)      74 (28.91)     

   Smoker                                     47 (27.98)         10 (11.36)      57 (22.27)     

  Medication history, n (%)                                                                     0.4739[c](#tfn4-dddt-9-2847){ref-type="table-fn"}

   ACE inhibitors or ARBs                     87 (51.79)         52 (59.09)      139 (54.30)    

   Calcium channel blockers                   71 (42.26)         31 (35.23)      102 (39.84)    

   Beta blockers                              24 (14.29)         17 (19.32)      41 (16.02)     

   Diuretics                                  16 (9.52)          9 (10.23)       25 (9.77)      

   Lipid modifying agents                     3 (1.79)           --              3 (1.17)       

   Alpha-blockers                             1 (0.60)           --              1 (0.39)       

   Cardiac drug                               --                 1 (1.14)        1 (0.39)       

   Peripheral vasodilators                    1 (0.60)           --              1 (0.39)       

  Drinking history, n (%)                                                                       0.0625[c](#tfn4-dddt-9-2847){ref-type="table-fn"}

   Non-drinker                                39 (23.21)         30 (34.09)      69 (26.95)     

   Drinker                                    129 (76.79)        58 (65.91)      187 (73.05)    

  Mean duration of hypertension, years (SD)   6.20 (6.02)        6.59 (5.84)     6.33 (5.95)    0.4465[b](#tfn3-dddt-9-2847){ref-type="table-fn"}

  Baseline blood pressure, mmHg (SD)                                                            

   Diastolic                                  96.8 (5.70)        96.5 (5.40)                    0.7078[a](#tfn2-dddt-9-2847){ref-type="table-fn"}

   Systolic                                   150.8 (12.70)      149.4 (11.90)                  0.3994[a](#tfn2-dddt-9-2847){ref-type="table-fn"}
  -----------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Difference between treatment groups by

two-sample *t*-test,

Wilcoxon rank-sum test, or

chi-square test.

**Abbreviations:** ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; HCTZ, hydrochlorothiazide; SD, standard deviation.

###### 

Means of sitting diastolic and systolic blood pressure at Weeks 4 and 8

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Visit                                                Fimasartan/HCTZ\   Fimasartan\    Difference in\   95% confidence interval   *P*-value[\*](#tfn9-dddt-9-2847){ref-type="table-fn"}
                                                       (N=168)            (N=88)         change ± SD                                
  ---------------------------------------------------- ------------------ -------------- ---------------- ------------------------- -------------------------------------------------------
  siDBP (mmHg)                                                                                                                      

   Baseline                                            96.81±5.65         96.53±5.44                                                

   Week 4                                              89.93±9.14         93.16±8.87                                                

   Change[a](#tfn7-dddt-9-2847){ref-type="table-fn"}   −6.88±8.10         −3.38±7.33     −3.50±7.84       −5.53, −1.47              0.0008

   Week 8                                              88.14±9.65         91.51±9.84                                                

   Change[b](#tfn8-dddt-9-2847){ref-type="table-fn"}   −8.67±9.39         −5.02±8.27     −3.65±9.02       −5.99, −1.31              0.0023

  siSBP (mmHg)                                                                                                                      

   Baseline                                            150.77±12.65       149.40±11.87                                              

   Week 4                                              140.27±15.55       143.65±14.76                                              

   Change[a](#tfn7-dddt-9-2847){ref-type="table-fn"}   −10.50±13.76       −5.75±12.18    −4.75±13.24      −8.18, −1.32              0.0069

   Week 8                                              137.32±15.90       142.56±16.22                                              

   Change[b](#tfn8-dddt-9-2847){ref-type="table-fn"}   −13.45±15.15       −6.84±13.57    −6.61±14.63      −10.40, −2.82             0.0007
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Data are expressed as mean ± SD.

Change from baseline at Week 4;

change from baseline at Week 8;

*P*-value by two-sample *t*-test.

**Abbreviations:** HCTZ, hydrochlorothiazide; SD, standard deviation; siDBP, sitting diastolic blood pressure; siSBP, sitting systolic blood pressure.

###### 

Means of sitting diastolic and systolic blood pressure in nonresponders at Week 4 of high-dose treatment

  ---------------------------------------------------------------------------------------------------
  Visit                                                    Fimasartan/HCTZ\            Fimasartan\
                                                           (N=74)                      (N=47)
  -------------------------------------------------------- ------------------ -------- --------------
  siDBP (mmHg)                                                                         

   Week 4                                                  97.93±5.64                  97.28±4.64

   Week 8                                                  91.51±9.88                  93.64±8.26

   Change                                                  −5.72±9.34                  −3.64±6.97

   *P*-value[a](#tfn12-dddt-9-2847){ref-type="table-fn"}   \<0.0001                    0.0008

   *P*-value[b](#tfn13-dddt-9-2847){ref-type="table-fn"}                      0.1922   

  siSBP (mmHg)                                                                         

   Week 4                                                  150.32±13.00                151.34±9.28

   Week 8                                                  142.46±16.64                149.89±12.67

   Change                                                  −7.86±15.40                 −4.45±11.45

   *P*-value[a](#tfn12-dddt-9-2847){ref-type="table-fn"}   \<0.0001                    0.0107

   *P*-value[b](#tfn13-dddt-9-2847){ref-type="table-fn"}                      0.1943   
  ---------------------------------------------------------------------------------------------------

**Notes:** Data are expressed in mean ± SD.

Paired *t*-test between Week 4 and 8.

Two-sample *t*-test of blood pressure change between groups.

**Abbreviations:** HCTZ, hydrochlorothiazide; SD, standard deviation; siDBP, sitting diastolic blood pressure; siSBP, sitting systolic blood pressure.

###### 

Drug-related adverse events with an incidence of \>1% in safety-analysis population

  Drug-related adverse event   Number (%) of subjects with ADRs                
  ---------------------------- ---------------------------------- ------------ ------------
  Total                        20 (11.43)                         11 (12.50)   31 (11.79)
  *P*-value                                                                    0.7993
  Headache                     4 (2.29)                           6 (6.82)     10 (3.80)
  Dizziness                    8 (4.57)                           3 (3.41)     9 (3.42)

**Abbreviations:** HCTZ, hydrochlorothiazide; ADRs, adverse drug reactions.
